Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Public Health.
Alzheimers Dement
December 2024
University of Kentucky College of Public Health, Lexington, KY, USA.
Background: Gabapentin has been increasingly prescribed to older adults for off-label indications, and accumulating evidence suggests potential for gabapentin misuse and related adverse events. However, the relation between gabapentin initiation and longer-term neurocognitive changes is not well understood.
Method: A retrospective cohort study was conducted using the National Alzheimer's Coordinating Center Uniform Data Set (2005-March 2023).
Public Health.
Alzheimers Dement
December 2024
Newcastle University, Newcastle Upon Tyne, United Kingdom.
Background: Evidence from epidemiological and clinical studies of the effect of anti-inflammatory medication on dementia risk has been mixed. Over the past two decades there has been recurring epidemiological evidence that the use of NSAID's for chronic inflammatory conditions is associated with a lower incidence of dementia.
Method: Cognitive Function and Ageing Study (CFAS) undertook baseline interviews in populations aged 65+ years in England and Wales (1989-1994).
A Double-Blind Comparative Study of burstDR Versus Tonic Epidural Motor Cortex Stimulation for the Treatment of Intractable Neuropathic Pain.
Eur J Pain
February 2025
Department of Neurosurgery, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France.
Background: Preliminary studies on epidural motor cortex stimulation (eMCS) for the treatment of drug-resistant neuropathic pain have supported the extension to novel stimulation waveforms, in particular burstDR. However, only a low level of evidence is available. The aim of this retrospective observational study was to compare the analgesic efficacy of burstDR versus tonic eMCS.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: The U.S. Population is older today than it has ever been.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Merry Life Biomedical Company, Ltd., Tainan City, Taiwan, Taiwan.
Background: Alzheimer's disease (AD) is complex in pathogenesis and related to aging biology, especially in late-onset AD. We identified a novel synthetic curcumin analog TML-6 through the platform of 6 biomarkers of anti-aging, anti-inflammation, and anti-Aβ as the potential AD drug candidate. TML-6 exhibits multi-target effects on AD pathogenesis, including the activation of NrF-2, the regulation of autophagic machinery through mTOR, the inhibition of APP synthesis and reduction of Aβ, the upregulation of ApoE, and the inhibition of microglial activation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!